Comparison of iRECIST and RECIST 1.1 for Evaluating Immunotherapy in Melanoma and Non-Small Cell Lung Cancer
In a retrospective study conducted at the University Hospital Cologne, the radiological criteria iRECIST and RECIST 1.1 were compared for assessing…
University Hospital Cologne: Comparison of iRECIST and RECIST 1.1 for Evaluating Immunotherapy in Melanoma and Non-Small Cell Lung Cancer
A retrospective study conducted at University Hospital Cologne compared two criteria for assessing therapeutic response to immunotherapy: iRECIST and…
Software-Assisted CT Assessment Outperforms Manual Methods in Oncology Study
A recent study conducted at UKE Hamburg compared manual and software-assisted assessments of computed tomography (CT) scans according to iRECIST…
UKE Hamburg: Study Shows that Software-Assisted Assessments Enhance iRECIST Evaluation
This research study [1] aimed to compare the feasibility and reliability of manual versus software-assisted assessments of computed tomography (CT)…
Scientifically proven benefits of mint Lesion™ in clinical routine
In contrast to clinical trials, unstructured free-text reporting is still common in the clinical routine. Such reports often lack content and clarity,…
New iRECIST whitepaper published
We are happy to present our newly published whitepaper on iRECIST and its application. This is available here on our homepage as well as on www.irecis…
New iRECIST Oncologic Response Criteria already in clinical use at the University Medical Center – Tübingen, Germany
Shortly following the release of the new iRECIST- oncologic response criteria (Lancet Oncology, March 2017) the University Medical Center in Tübingen,…
Novel oncologic therapy response criteria (iRECIST and more)
Advances in oncology therapies, such as novel immune-related agents, require adapted and refined criteria and guidelines for the assessment and…
About Cookies
This website uses cookies. Those have two functions: On the one hand they are providing basic functionality for this website. On the other hand they allow us to improve our content for you by saving and analyzing anonymized user data. You can redraw your consent to using these cookies at any time. Find more information regarding cookies on our Data Protection Declaration and regarding us on the Imprint.
